ArticleHealth economics review2026
Costs and cost-effectiveness of type 2 diabetes management in Sub-Saharan Africa: a systematic review.
Article in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 Diabetes (T2D) is rapidly increasing in Sub-Saharan Africa (SSA), with related health and financial implications. Knowledge of the costs and cost-effectiveness of managing diabetes is needed to increase awareness, improve resource allocation and enhance the use of evidence-based decision-making. Accordingly, this study sought to synthesise and critically review evidence on the costs and cost-effectiveness of managing T2D in Sub-Saharan Africa (SSA).
methodsA systematic search was conducted in multiple databases, including PubMed-Medline, Africa-Wide Information, Web of Science, Cochrane Library, CINAHL, Scopus, and Google Scholar, to identify studies published between January 2010 and December 2023; the searches were updated in June 2024. All cost data were converted to 2024 United States dollars (US$) using appropriate inflation adjustments and exchange rates. The review protocol was registered with PROSPERO (CRD42022300580).
resultsThe search yielded 4137 unique abstracts, and 18 studies were included for review, most originating from Nigeria. Most studies assessed costs from a provider perspective, focusing on direct medical costs (e.g., outpatient consultations, medications, diagnostic and monitoring tests, and follow-up care). Reported costs of T2D management were substantial across settings. Annual costs ranged from US$337.50 for basic medical care of uncomplicated T2D to US$2330.74 in total provider cost per patient. The highest burden was reported among individuals in the low-income quantile. Only five studies assessed cost-effectiveness, most using modelling and simulation approaches. T2D management programmes can be cost-effective, but the evidence remains limited.
conclusionsThis review identified substantial variation in methods, perspectives, and cost components across T2D cost studies in SSA, which limits direct comparability. Improving methodological transparency and reporting, alongside addressing data-collection gaps, would strengthen the evidence base. Further context-specific economic evaluations, particularly those incorporating affordability, implementation feasibility, and budget impact, are needed to support priority setting and resource allocation for T2D management in SSA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.